Apr 3, 2024, 06:05
Most viewed in the last 7 days from JAMA Oncology
JAMA Oncology shared a post on LinkedIn:
“Most viewed in the last 7 days from JAMA Oncology: Do patients with resectable NSCLC and tumor programmed cell death 1 ligand 1 levels less than 1% benefit from neoadjuvant chemo immunotherapy?”
Additional information.
Source: JAMA Oncology/LinkedIn